This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
May 2, 2026
•
15 min read
Why securitization might be the way towards greater CGT and advanced therapy access
May 1, 2026
4 min read
🧬 Axsome Therapeutics' Auvelity (dextromethorphan/bupropion) receives FDA approval for agitation associated with Alzheimer's disease dementia, AstraZeneca licenses preclinical EGFR degrader from Pinetree Therapeutics for $25M, up to $500M milestones, UniQure to seek UK approval for Huntington's gene therapy AMT-130, shares surge 20%
Apr 30, 2026
3 min read
🧬 GSK's Shingrix strategy shift targeting comorbid patients drives $1.4B Q1 sales, beating analyst forecasts, Chiesi acquires KalVista Pharmaceuticals for $1.9B, gaining rare disease oral HAE treatment Ekterly, Avalyn Pharma raises $300M IPO to develop drugs for hard-to-treat lung diseases
Apr 29, 2026
🧬 AbbVie gains exclusive right to acquire Kestrel Therapeutics for up to $1.45B - targeting oral pan-KRAS inhibitor, Coultreon Biopharma raises $125M Series A to advance oral SIK3 autoimmune drug, Rocket Pharmaceuticals sells rare pediatric disease priority review voucher for $180M, Eli Lilly + Profluent Bio partner on AI-designed DNA editing tools for genetic medicines - up to $2.25B milestones
Apr 28, 2026
🧬 Rejuvenate Bio launches crowdfunding campaign to advance gene therapy for aging + chronic diseases, Intellia Therapeutics' lonvo-z succeeds in Ph3 trial for hereditary angioedema - company begins rolling FDA submission, Thermo Fisher Scientific divests microbiology business to Astorg for $1.075B, UK biotech VC funding rises 17% in Q1 2026 - showing recovery signs but IPO activity remains stagnant
Apr 27, 2026
🧬 Sun Pharma to acquire Organon for $12.5B in largest-ever overseas deal by Indian company, FDA awards national priority vouchers to Compass Pathways + Transcend Therapeutics + Usona Institute for psychedelic treatments, Johnson & Johnson launches 4 prescription drugs on Trump administration's TrumpRx discounted pharmaceutical website, EMA recommends approval of Sanofi's tolebrutinib for secondary progressive multiple sclerosis after FDA rejection
Apr 24, 2026
🧬 Kurma Partners closes €215M ($251M) Biofund IV to back around 20 European biotechs, Regeneron Pharmaceuticals' Otarmeni wins FDA approval for otoferlin-deficient congenital hearing loss following Ph1/2 success, Evonik invests €80M ($93.6M) in Slovakia facility to boost fermentation capabilities - adding 50 jobs, Novo Nordisk's Rybelsus (semaglutide) meets Ph3 goals in pediatric type 2 diabetes + supporting label expansion filings
Apr 23, 2026
🧬 Merck & Co. + Google Cloud partner on enterprise-wide agentic AI transformation, investment valued up to $1B, AbbVie invests $1.4B to build 185-acre Durham NC production hub - creating 730-plus jobs, Amneal acquires Kashiv BioSciences for $1.1B to expand biosimilars pipeline amid market growth, Moderna's mCOMBRIAX (mRNA-1010/mNEXSPIKE) wins European Commission approval for influenza and COVID-19 combination immunization in adults 50 and older
Apr 22, 2026
🧬 Ray Therapeutics raises $125M Series B for genetic retinal degeneration gene therapy, Flagship Pioneering launches Serif Biomedicines with $50M to develop novel modified DNA genetic medicines, AstraZeneca's Ultomiris (ravulizumab) meets primary endpoint in Ph3 trial for immunoglobulin A nephropathy, Merck & Co.'s Idvynso (doravirine/islatravir) wins FDA approval for virologically suppressed adults with human immunodeficiency virus following Ph3 success
Apr 21, 2026
🧬 Eli Lilly acquires Kelonia Therapeutics for up to $7B to expand in vivo CAR-T capabilities, AstraZeneca's (tozorakimab) meets primary endpoint in Ph3 trial for chronic obstructive pulmonary disease, Biogen + TJ Biopharma expand partnership for China rights to felzartamab - $100M upfront + $850M biobucks
Apr 20, 2026
🧬 Former Genentech leader unveils Synthetic Design Lab - developing adaptive "smart" ADC cancer drugs, UCB to acquire Neurona Therapeutics for up to $1.2B - expanding into seizure cell therapy, Merck & Co. unveils Ph1/Ph2 data for MK-2010 (MK-2010) - PD-1xVEGF bispecific in non-small cell lung cancer
Apr 18, 2026
🧬 From policy to production: how China is scaling synthetic biology - and what it means for global competition
Apr 17, 2026
🧬 Kailera Therapeutics prices massive $625M IPO for advancing next-generation obesity care treatments, Roche launches new Phase III study to pursue EU approval for DMD gene therapy Elevidys, Aligos Therapeutics + Amoytop ink $445M deal licensing HBV drug pevifoscorvir sodium China rights
Apr 16, 2026
🧬 Spain plans $200M VC fund bridging Spanish biotechs with Boston's life science ecosystem, Beeline Medicines debuts with $300M Series A - licensing five Bristol Myers immune disease drug candidates, Sandoz signs manufacturing and supply agreement with Rwanda government to provide critical medicines across Africa
Apr 15, 2026
8 min read
🧬 Novo Nordisk + OpenAI partner to integrate AI across drug discovery + manufacturing + corporate operations, Amazon Web Services launches Amazon Bio Discovery AI tool to accelerate antibody design and drug discovery, Eli Lilly acquires CrossBridge Bio for up to $300M to advance dual-payload ADC cancer pipeline, Alamar Biosciences files for $159M IPO - protein sequencing and biomarker profiling tools, Harbinger Health raises $100M to develop RESOLVE multi-cancer liquid biopsy detection tests
Apr 14, 2026
🧬 Kailera plans $528.5M IPO to advance quartet of Chinese obesity assets, Eli Lilly's Jaypirca hits Ph3 endpoint for chronic lymphocytic leukemia in fixed-duration combination therapy, AbbVie + Haisco Pharmaceutical partner on pain compounds development - up to $715M deal value
Apr 13, 2026
7 min read
🧬 Sun Pharma readies $12B binding offer to acquire women's health company Organon amid competing bids, Vivatides Therapeutics raises $54M Series A for RNA delivery beyond the liver, GSK advances mocertatug rezetecan (Mo-Rez) targeting B7-H4 to Ph3 trials for ovarian and endometrial cancers
Apr 11, 2026
24 min read
Why the biotech of the future might be a lot smaller and a lot more nimble
Apr 10, 2026
🧬 Eli Lilly launches obesity pill Foundayo at $149 - intensifying GLP-1 competition with Novo Nordisk's Wegovy, Genentech receives FDA approval for updated Vabysmo (faricimab-svoa) label extending macular edema treatment beyond six months, Avalyn Pharma plans IPO - developing inhalable IPF treatments for lung disease, Invivyd prepares VMS063 antibody targeting fusion protein for Ph1 testing in measles treatment and prevention, Boehringer Ingelheim hands Click Therapeutics marketing rights to schizophrenia PDT CT-155 + $50M investment
Apr 9, 2026
🧬 Jeito Capital raises $1.2B fund - investing in European clinical-stage drugmakers, Shionogi lands US BARDA contract for Fetroja antibiotic manufacturing - $482M potential value, Gilead Sciences pauses M&A after acquiring Arcellx + Ouro Medicines + and Tubulis within six weeks
Apr 8, 2026
🧬 Gilead Sciences to acquire German biotech Tubulis for $3.1B upfront in ADC deal, E2 raises $80M Series C for next-gen thrombectomy treatment commercialization, Vertex Pharmaceuticals + Halozyme partner on Hypercon drug delivery technology - $15M upfront plus milestones
Apr 7, 2026
🧬 Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9B in “surprising” acquisition - gaining rare obesity disorder drug Vykat XR, Stipple Bio emerges from stealth with $100M Series A to develop tumor-specific epitope-targeting ADCs, Amgen's subcutaneous Tepezza (teprotumumab) meets Ph3 endpoints for thyroid eye disease treatment
Apr 6, 2026
9 min read
🧬 Anthropic acquires stealth biotech Coefficient Bio for $400M to expand AI-driven drug research and development capabilities, Novo Nordisk claims indirect data show oral Wegovy outperforms Eli Lilly's Foundayo in obesity treatment comparison, Transgene licenses NEC Bio's AI neoantigen prediction platform for TG4050 - €5M ($5.77M) plus milestones
Apr 2, 2026
🧬 Eli Lilly's Foundayo (orforglipron) wins FDA approval for obesity treatment following Ph3 success, Korsana Biosciences to go public via Cyclerion Therapeutics reverse merger with $380M funding, Syneron Bio raises $150M Series B, advancing macrocyclic peptide drug discovery platform
Apr 1, 2026
🧬 Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B to enter sleep disorder market - ultimately challenging Takeda, Ambrosia Biosciences raises $100M Series B - developing oral weight-loss medications, BMS + Faro partner on multi-year AI clinical trial protocol improvement agreement
